A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of HS-20094 injection in subjects with type 2 diabetes who have inadequate glycemic control with diet and exercise alone. The primary objective of this study is to evaluate the effectiveness of HS-20094 compared to placebo in controlling blood glucose levels after 44 weeks and 52 weeks treatment.

NCT Number	NCT07156500
Lead Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions	Type 2 Diabetes
Enrollment	204 participants
Start Date	2025-09-30
Primary Completion	2027-03-30 (estimated)
Study Completion	2027-05-30 (estimated)
Updated on ClinicalTrials.gov	2025-09-05